Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 7/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.34 |
| ▸ | METAP1 | P53582 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26323396 | 0.82 | NPC1 (0.48) | NPC1RAB9APKMACHECHEK2 | |
| SCHEMBL26323315 | 0.78 | CBFB (0.34) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL26158811 | 0.74 | METAP2 (0.52) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL26158835 | 0.69 | CBFB (0.47) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL179155 | 0.69 | CBFB (0.63) | CBFBNPC1RAB9APKMRUNX1 | |
| SCHEMBL26323357 | 0.68 | ADRA2A (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL124413 | 0.67 | CBFB (0.58) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL35032 | 0.67 | CBFB (0.50) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL125273 | 0.67 | KCNH2 (0.45) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL125204 | 0.67 | CBFB (0.54) | CBFBMETAP2METAP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | CBFB 3072/4885METAP2 3851/4885METAP1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.